Appclon Announces Final Phase 1 Clinical Results of CAR-T Therapy at ASCO

"New CAR-T Therapy Expected to be Introduced"

Appclon announced on the 28th that it will participate in the 2023 American Society of Clinical Oncology (ASCO) conference held in Chicago from June 2 to 6, where it will present the Phase 1 clinical trial results of its chimeric antigen receptor (CAR)-T therapy 'AT101.'

Abclon CI. [Image provided by Abclon]

AT101 uses the h1218 antibody developed through Appclon's proprietary antibody development platform 'NEST.' Appclon emphasized that this differentiates it from the four currently commercialized CD19 CAR-T therapies, all of which use the mouse-derived FMC63 antibody.

The presentation will be led by Professor Yoon Deok-hyun, director of the CAR-T Center at the Asan Medical Center Cancer Hospital in Seoul, who is overseeing the AT101 clinical trial. The results from multiple institutions participating in the clinical trial will be summarized, including the efficacy and safety of AT101 confirmed in Phase 1. Following the interim presentation at the American Association for Cancer Research (AACR) on the 17th (local time), ASCO will disclose results for all patients enrolled in the Phase 1 trial. Administration to Phase 1 patients has been completed, and follow-up measures are being taken according to treatment progress.

An Appclon representative stated, "The h1218 antibody acts on a different part of the CD19 disease protein than the site targeted by the FMC63 antibody, thereby demonstrating differentiated effects compared to existing CAR-T therapies," adding, "We expect to secure a unique market position in the CD19-targeted CAR-T therapy market."

Meanwhile, Appclon is also co-developing a new CAR-T therapy targeting CD30 with Professor Marco Ruella of the University of Pennsylvania School of Medicine and is in the process of filing patents for the research outcomes. The research results for this therapy will be presented at the International Society for Cell & Gene Therapy (ISCT) conference held in Paris, France, starting on the 30th of next month.

This content was produced with the assistance of AI translation services.